Cargando…

Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review

Nowadays, immune checkpoint inhibitor therapy has been used in more and more cancer patients. These agents were associated with immune-related adverse effects, and autoimmune diabetes mellitus is one of them. And it is not common but can be potentially fatal. Anti PD-1 monoclonal antibody is a human...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wei, Wang, Hao, Chen, Bin, Zhao, Sha, Zhang, Xiaoshen, Jia, Keyi, Deng, Juan, He, Yayi, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225154/ https://www.ncbi.nlm.nih.gov/pubmed/32420079 http://dx.doi.org/10.21037/tlcr.2020.03.05

Ejemplares similares

Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment
por: Wang, Hao, et al.
Publicado: (2019)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer
por: Sun, Chenglong, et al.
Publicado: (2020)

CD137, an attractive candidate for the immunotherapy of lung cancer
por: Ye, Lingyun, et al.
Publicado: (2020)

Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
por: Jiang, Minlin, et al.
Publicado: (2021)

Alterations of DNA damage repair in cancer: from mechanisms to applications
por: Jiang, Minlin, et al.
Publicado: (2020)

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

Immunotherapy as a treatment for small cell lung cancer: a case report and brief review
por: Wu, Yan, et al.
Publicado: (2020)

Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review
por: Chen, Shen, et al.
Publicado: (2019)

Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD‐1 inhibitor therapy
por: Fang, Qiyu, et al.
Publicado: (2022)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
por: Bellastella, Giuseppe, et al.
Publicado: (2021)

The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection
por: Shi, Jinpeng, et al.
Publicado: (2021)

Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
por: Chen, Yu, et al.
Publicado: (2021)

Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
por: Du, Fanny Huynh, et al.
Publicado: (2017)

Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin
por: Ly, Sophia, et al.
Publicado: (2023)

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
por: Liu, Sangtian, et al.
Publicado: (2021)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
por: Faiena, Izak, et al.
Publicado: (2018)

Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
por: Jolly, Elaine C., et al.
Publicado: (2009)

Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab
por: Parker, Matthew JS, et al.
Publicado: (2018)

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
por: Zhang, Shuang, et al.
Publicado: (2018)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

New Onset Autoimmune Diabetes Mellitus, Autoimmune Thyroiditis and Subsequent Autoimmune Hepatitis With Monoclonal Antibody to Programmed Cell Death-1 (PD-1) Protein Therapy in a Patient With Non Small Cell Lung Cancer: 18 Months Follow up Experience
por: Mandal, Kaushik, et al.
Publicado: (2021)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

Polyspecificity of antistreptococcal murine monoclonal antibodies and their implications in autoimmunity
Publicado: (1986)

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development
por: Phakham, Tanapati, et al.
Publicado: (2022)

Brief Report - Monoclonal Antibodies Illustrate the Difficulties in Measuring Blocking TSH Receptor Antibodies
por: Davies, Terry F., et al.
Publicado: (2022)

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes
por: He, Yayi, et al.
Publicado: (2017)

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies
por: Metzger, Philipp, et al.
Publicado: (2018)

Intravenous Delivery of RNA Encoding Anti-PD-1 Human Monoclonal Antibody for Treating Intestinal Cancer
por: Wu, Lipei, et al.
Publicado: (2022)

Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress
por: Torrente-López, Anabel, et al.
Publicado: (2022)

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies
por: Wang, Xuan, et al.
Publicado: (2020)

Monoclonal Antibodies From Anti-NMDA Receptor Encephalitis Patient as a Tool to Study Autoimmune Seizures
por: Taraschenko, Olga, et al.
Publicado: (2021)

Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies
por: Briani, Chiara, et al.
Publicado: (2022)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Commentary: Brief report - Monoclonal antibodies illustrate the difficulties in measuring blocking TSH receptor antibodies
por: Olivo, Paul D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bekkgn0fpnqcvgq4inmm41laud